CAHP Cardiac Arrest Hospital Prognosis Score
Clinical score predicting neurological outcome (CPC 1 or 2 at 30 days) in patients resuscitated from out-of-hospital cardiac arrest. Based on 7 variables at ED arrival. Validated in French multicentre cohorts. Low score indicates favourable neurological outcome.
Score interpretation
Poor neurological outcome (CPC 3–5) in about 39 % in the derivation cohort.
→ Standard post-resuscitation care; prognosticate with multimodal assessment, not this score alone.
Poor neurological outcome in about 81 %.
→ Multimodal neuroprognostication before any decision; discuss with the family.
Poor neurological outcome in 100 % of the derivation cohort.
→ Early, honest goals-of-care discussion alongside multimodal prognostication.
Interpretation bands for the CAHP Score. Apply clinical judgement and local guidance.
References
- Maupain C, et al. The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. Eur Heart J. 2016;37(42):3222–3228.
Related
Curated clinical cross-links plus same-class fallbacks.
- Amiodarone (IV — ICU/Peri-Arrest) · Antiarrhythmic (Class III)
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Lisinopril (HFrEF / Post-MI) · ACE Inhibitor / HFrEF
- Colchicine (Pericarditis / Post-MI Inflammation) · Pericarditis / Coronary Inflammation
- Clopidogrel (ACS / Post-PCI) · Antiplatelet / ACS
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.